Here is the tension in one sentence: the new anti-amyloid drugs (lecanemab and donanemab) treat a disease APOE4 carriers are at higher risk for, and their main side effect is also more common in carriers. The benefit is modest: lecanemab slowed decline by about 27% over 18 months (roughly a few months’ worth of difference), not a reversal.
ARIA is an MRI finding (magnetic resonance imaging, a scan that uses magnets and radio waves rather than X-rays), not a synonym for symptoms; the full anti-amyloid evidence review explains the mechanism and genotype-specific rates. If this affects a real treatment decision, first review how APOE testing should be confirmed clinically and bring the monitoring questions to the treating specialist.
The side effect is ARIA (amyloid-related imaging abnormalities: brain swelling or small bleeds on MRI), and the genotype gradient is steep. In the lecanemab trial, ARIA-E occurred in about 5% of non-carriers, 11% of one-copy carriers, and 33% of ε4/ε4 homozygotes. That is why APOE genotyping is now done before starting, and why eligibility can hinge on your genotype: the EU, for instance, approved lecanemab only for non-carriers and heterozygotes, excluding ε4/ε4 homozygotes.
The practical upshot: these are treatments for early, confirmed disease, not a general carrier intervention, and genotype affects both eligibility and the risk-and-benefit calculation. We unpack it in the deep dive on anti-amyloid drugs and APOE4.